00:18 , Dec 22, 2017 |  BC Week In Review  |  Company News

Zai gets Chinese rights to Five Prime's mAb

Five Prime Therapeutics Inc. (NASDAQ:FPRX) granted Zai Lab Ltd. (NASDAQ:ZLAB) exclusive rights to develop and commercialize FPA144 in China, Hong Kong, Macau and Taiwan. The therapy is a humanized mAb against keratinocyte growth factor (KGF)...
01:20 , Dec 20, 2017 |  BC Extra  |  Company News

Zai gets Chinese rights to Five Prime's mAb

Five Prime Therapeutics Inc. (NASDAQ:FPRX) granted Zai Lab Ltd. (NASDAQ:ZLAB) exclusive rights to develop and commercialize FPA144 in China, Hong Kong, Macau and Taiwan. The therapy is a humanized mAb against keratinocyte growth factor (KGF)...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

FPA144: Additional Phase I data

Data from 9 patients with FGFR2b-positive gastric cancer in the dose-escalation Part 1 of an open-label, international Phase I trial showed that 6-15 mg/kg IV FPA144 every 2 weeks led to an ORR of 33%,...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

FPA144: Preliminary Phase I data

Preliminary data from 27 patients with solid tumors in the dose-escalation Part 1 of an open-label, U.S. Phase I trial showed that doses of up to 15 mg/kg IV FPA144 every 2 weeks were well...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

FPA144: Phase I started

Five Prime began a 2-part, open-label, U.S. Phase I trial to evaluate IV FPA144 every 2 weeks in about 100 patients. The dose-escalation part will enroll about 30 patients with solid tumors, and the dose-expansion...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Company News

Five Prime, Lonza, Kyowa Hakko Kirin deal

Five Prime received rights from Lonza and Kyowa's BioWa Inc. subsidiary to apply the Potelligent CHOK1SV cell line technology to antibodies in Five Prime's cancer pipeline. Potelligent CHOK1SV cell line increases antibody-dependent cellular cytotoxicity...